慢性阻塞性肺疾病是一种常见的慢性呼吸系统疾病,以慢性呼吸道症状及持续性气流受限为特征,常表现为反复咳嗽、咳痰、进行性加重的呼吸困难等症状。慢阻肺为目前全球前三大死亡原因之一,许多患者长年遭受疾病的折磨,造成重大并逐年攀升...慢性阻塞性肺疾病是一种常见的慢性呼吸系统疾病,以慢性呼吸道症状及持续性气流受限为特征,常表现为反复咳嗽、咳痰、进行性加重的呼吸困难等症状。慢阻肺为目前全球前三大死亡原因之一,许多患者长年遭受疾病的折磨,造成重大并逐年攀升的经济和社会负担。2024年9月27日,度普利尤单抗被中国国家药品监督管理局(NMPA)批准,用于血嗜酸性粒细胞升高且控制不佳的慢性阻塞性肺疾病成人患者。目前关于度普利尤单抗用于治疗慢阻肺的研究报道较少,对于度普利尤单抗的安全性认识不足。本文针对度普利尤单抗在慢性阻塞性肺疾病治疗中的机制及安全性进行综述,以期为临床提供治疗参考及慢阻肺治疗开发提供新的途径。Chronic obstructive pulmonary disease is a common chronic respiratory disease characterized by chronic respiratory symptoms and persistent airflow limitation, often manifested as recurrent coughing, sputum production, progressively worsening dyspnea and other symptoms. Chronic obstructive pulmonary disease (COPD) is currently one of the top three causes of death worldwide, and many patients suffer from the disease for years, causing significant and increasing economic and social burdens. On September 27, 2024, dupilumab was approved by the National Medical Products Administration (NMPA) of China for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. At present, there are few research reports on the use of dupilumab for the treatment of chronic obstructive pulmonary disease, and there is insufficient understanding of the safety of dupilumab. This article reviews the mechanism and safety of dupilumab in the treatment of chronic obstructive pulmonary disease, aiming to provide clinical references and new approaches for the development of COPD treatment.展开更多
文摘慢性阻塞性肺疾病是一种常见的慢性呼吸系统疾病,以慢性呼吸道症状及持续性气流受限为特征,常表现为反复咳嗽、咳痰、进行性加重的呼吸困难等症状。慢阻肺为目前全球前三大死亡原因之一,许多患者长年遭受疾病的折磨,造成重大并逐年攀升的经济和社会负担。2024年9月27日,度普利尤单抗被中国国家药品监督管理局(NMPA)批准,用于血嗜酸性粒细胞升高且控制不佳的慢性阻塞性肺疾病成人患者。目前关于度普利尤单抗用于治疗慢阻肺的研究报道较少,对于度普利尤单抗的安全性认识不足。本文针对度普利尤单抗在慢性阻塞性肺疾病治疗中的机制及安全性进行综述,以期为临床提供治疗参考及慢阻肺治疗开发提供新的途径。Chronic obstructive pulmonary disease is a common chronic respiratory disease characterized by chronic respiratory symptoms and persistent airflow limitation, often manifested as recurrent coughing, sputum production, progressively worsening dyspnea and other symptoms. Chronic obstructive pulmonary disease (COPD) is currently one of the top three causes of death worldwide, and many patients suffer from the disease for years, causing significant and increasing economic and social burdens. On September 27, 2024, dupilumab was approved by the National Medical Products Administration (NMPA) of China for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. At present, there are few research reports on the use of dupilumab for the treatment of chronic obstructive pulmonary disease, and there is insufficient understanding of the safety of dupilumab. This article reviews the mechanism and safety of dupilumab in the treatment of chronic obstructive pulmonary disease, aiming to provide clinical references and new approaches for the development of COPD treatment.
